DFTX Phase 3 DT120 ODT 100 mcg meets GAD endpoints
A Phase 3 Panorama study in generalized anxiety disorder (GAD) reported that DT120 ODT 100 mcg met all primary and key secondary endpoints, with favorable safety and sustained efficacy in interim extension data (partial).